A Biotech With a Growing Moat
Regeneron's moat is widening thanks to recent clinical successes and a productive pipeline; however, investors should wait for a better price before buying.
Regeneron's moat is widening thanks to recent clinical successes and a productive pipeline; however, investors should wait for a better price before buying.
Stefan Quenneville: Regeneron (REGN) is a biotechnology company that we rate as having a narrow moat and a positive moat trend. We think its positive moat trend is driven by its recent string of clinical and commercial successes, as well as its very full and productive drug-development pipeline.
The company turned profitable in 2012, largely due to its key drug Eylea, which is a growing blockbuster that treats degenerative eye diseases. What's really important, though, from a moat perspective is the company's ability to reinvest those profits to develop new drugs that target attractive market opportunities. This is a very challenging thing to do for a lot of biotechs; a lot of biotechs fail here. But Regeneron has been able to do this successfully, and we really think this is what's driving its long-term competitive advantage, or its moat.
Currently, the company has 16 drugs in clinical development, including three very promising drugs in Phase III. We think each of those Phase III drugs has the opportunity to be a blockbuster in its own right. So overall, this strong R&D productivity, as well as this progress in its pipeline, is really what's driving [Regeneron's] positive moat trend. Currently, the company is trading at a slight premium to our fair value of $365 per share, but we think investors should keep it on the radar screen in case they get a chance to buy it on a dip.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.